Friday 6 November 2026 Export BIO’s income statement to Excel — free account

Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024.

Revenue: +0.52%
EPS: +234.9%
Free cash flow: +8.07%
Total debt: +0.11%

Quarter to September 2026, against a year earlier

Operating cash flow growth 3 yrs

382.44 13.44 +3.64%

Follow BIO

Alert me

Market cap: $9.9B
P/E: 9.7×
Fwd P/E: 44.7×
Dividend yield: —
F-score: 5/9
Altman Z: 3.20
Beneish M: −2.29
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Bio-Rad Laboratories, Inc. 8-K filed Apr 24, 2026

Period ended Apr 21, 2026 · Filed Apr 24, 2026 · accepted 4:30 PM ET · Document on sec.gov · Filing index

5.02 Departure or appointment of directors or officers; 5.07 Submission of matters to a vote of security holders; 9.01 Financial statements and exhibits

Red flags

Officer departure Apr 24, 2026
Bio-Rad Laboratories, Inc. reported the departure of an officer or director

8-K filed Apr 24, 2026 · The filing · sec.gov

Bio-Rad Laboratories, Inc. 8-K filed Apr 24, 2026

Red flags

Stockrow Weekly